Modalities for the treatment of degenerative diseases of the retina
First Claim
Patent Images
1. A method of producing a human RPE preparation suitable for transplantation into the eye of a human patient in need thereof comprising:
- (a) differentiating in vitro human pluripotent cells that express Oct-4, alkaline phosphatase, SSEA-3, SSEA-4, TRA-I-60, and TRA-I-81 under conditions that do not maintain the undifferentiated state of the pluripotent cells to obtain a heterogeneous population of human cells including pigmented cells comprising brown pigment dispersed in their cytoplasm;
(b) isolating and culturing said pigmented cells from the heterogeneous cell population to obtain a monolayer comprising cells having a cobblestone, polygonal, epithelial-like appearance and brown pigment dispersed in their cytoplasm, and expressing RPE65 and bestrophin, and(c) isolating and purifying the RPE cells to form a composition suitable for human therapy.
5 Assignments
0 Petitions
Accused Products
Abstract
This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.
52 Citations
14 Claims
-
1. A method of producing a human RPE preparation suitable for transplantation into the eye of a human patient in need thereof comprising:
-
(a) differentiating in vitro human pluripotent cells that express Oct-4, alkaline phosphatase, SSEA-3, SSEA-4, TRA-I-60, and TRA-I-81 under conditions that do not maintain the undifferentiated state of the pluripotent cells to obtain a heterogeneous population of human cells including pigmented cells comprising brown pigment dispersed in their cytoplasm; (b) isolating and culturing said pigmented cells from the heterogeneous cell population to obtain a monolayer comprising cells having a cobblestone, polygonal, epithelial-like appearance and brown pigment dispersed in their cytoplasm, and expressing RPE65 and bestrophin, and (c) isolating and purifying the RPE cells to form a composition suitable for human therapy. - View Dependent Claims (4, 5, 10)
-
-
2. A method of producing a composition comprising isolated human RPE cells suitable for human therapy, comprising:
-
(a) allowing human pluripotent cells to overgrow and form a thick multilayer of cells; (b) culturing the pluripotent cells of step (a) under adherent conditions that do not maintain the undifferentiated state of the pluripotent cells for a sufficient time for the appearance of pigmented cells comprising brown pigment dispersed in their cytoplasm; and (c) isolating and culturing the pigmented cells to form a monolayer comprising cells having a cobblestone, polygonal, epithelial-like appearance and brown pigment dispersed in their cytoplasm, and expressing RPE65 and bestrophin, thereby obtaining human RPE cells. - View Dependent Claims (6, 7, 11, 12)
-
-
3. A method of producing a composition comprising isolated human RPE cells suitable for human therapy, comprising:
-
(a) providing a multilayer culture of human pluripotent cells; (b) culturing the multilayer culture of pluripotent cells of step (a) under adherent conditions that do not maintain the undifferentiated state of the pluripotent cells for a sufficient time for the appearance of pigmented cells comprising brown pigment dispersed in their cytoplasm; and (c) isolating and culturing the pigmented cells to form a monolayer comprising cells having a cobblestone, polygonal, epithelial-like appearance and brown pigment dispersed in their cytoplasm, and expressing RPE65 and bestrophin, thereby obtaining human RPE cells. - View Dependent Claims (8, 9, 13, 14)
-
Specification